Healthcare Industry News: deuterated chemical entity
News Release - January 19, 2011
James E. Shipley, M.D., Named Chief Medical Officer of Concert PharmaceuticalsAdditional Management Team Announcement with Promotion of Robert Silverman
LEXINGTON, Mass.--(Healthcare Sales & Marketing Network)-- Concert Pharmaceuticals, Inc. announced today the appointment of James E. Shipley, M.D., as its Chief Medical Officer. In this newly created position, Dr. Shipley will have responsibility for Concert's clinical research, clinical operations, regulatory affairs, quality assurance, and clinical pharmacology. He will report to Roger Tung, Ph.D., Concert’s President and Chief Executive Officer. Concert also announced that Robert Silverman, J.D., Ph.D. has been promoted to Senior Vice President and General Counsel.
“Jim Shipley is an accomplished clinician with extensive industry experience, having been involved in the development of more than two dozen compounds resulting in four New Drug Application approvals. With his broad medical background, especially in the area of CNS diseases, an area of increasing focus at Concert, he will be a tremendous asset as we advance our product pipeline,” said Dr. Tung. “We are pleased to welcome Jim to our leadership team and look forward to his contributions as programs from our DCE Platform™ continue to advance into and through clinical testing.”
Dr. Shipley joins Concert with more than 15 years of industry experience including extensive knowledge in clinical operations and regulatory affairs. Previously, he served as Senior Vice President of Clinical Development, Medical and Regulatory Affairs at Indevus Pharmaceuticals, which was subsequently acquired by Endo Pharmaceuticals. While at Indevus he provided medical and scientific oversight and developed regulatory strategies for more than a dozen compounds in various stages of development. Before joining Indevus, Dr. Shipley was Senior Vice President of Clinical Research at Praecis Pharmaceuticals, where he managed several clinical trials leading to a successful New Drug Application for a prostate cancer drug, as well as trials of compounds for Alzheimer's disease, non-Hodgkins lymphoma and pain indications. Previously, he held several positions of increasing responsibility with Aventis Pharmaceuticals, most recently as Senior Director of CNS Clinical Research. Prior to that, Dr. Shipley was an attending physician in the Mood Disorders program and Director of the Sleep Diagnostic and Research program at the University of Michigan.
Dr. Shipley received his M.D. from the University of Pittsburgh, an M.A. in psychology/neuroscience from the University of Western Ontario and an Honors B.A. from the Pennsylvania State University. He is board certified by the American Board of Psychiatry and Neurology and the American Board of Sleep Medicine.
Concert also announced today the promotion of Dr. Robert Silverman to Senior Vice President and General Counsel. Since joining Concert in January 2007, as Vice President and General Counsel, he has overseen all legal aspects at Concert, and notably played a key role implementing the company’s intellectual property strategy to enable numerous patent issuances in the US and abroad. Dr. Silverman has over 20 years of legal and scientific experience in biotechnology and chemical companies, including Millennium Pharmaceuticals, Vertex Pharmaceuticals and FMC Corporation. Dr. Silverman received his J.D. from Rutgers-Camden Law School. He also has an undergraduate degree from Lehigh University, a Ph.D. in organic chemistry from the University of New Mexico and conducted postdoctoral research in chemistry at Stanford University.
Concert Pharmaceuticals is a clinical stage biotechnology company focused on applying the company’s DCE Platform™ (deuterated chemical entity platform) to create novel and differentiated small molecule drugs. Concert’s approach leverages known activity and safety of existing drugs to reduce time, risk and expense of drug research and development. The Company has a broad research pipeline encompassing many therapeutic areas including infectious disease, renal disease and CNS disorders, among others. Founded in 2006, Concert has raised more than $110 million of venture and institutional capital. For more information on Concert Pharmaceuticals, please visit www.concertpharma.com.
Concert Pharmaceuticals, the CoNCERT logo and the DCE Platform are trademarks of Concert Pharmaceuticals, Inc.
Source: Concert Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.